NICE has recommended Gilead’s Epclusa as a treatment option for all genotypes of hepatitis C in first draft guidance. Trial data has shown recently-approved Epclusa (sofosbuvir+velpatasvir ...

The FDA has approved Gilead's Epclusa (sofosbuvir+velpatasvir) for hepatitis C, the first interferon-free combination treatment for all six major forms of the virus. The drug represented the next ...

The FDA just approved a new hepatitis C drug that works on all kinds of patients. The drug, Epclusa, is a combination of sofosbuvir (which was originally approved back in 2013) and velpatasvir (a ...

Louisiana’s subscription-based model for hepatitis C treatment dramatically increased diagnoses and cures while reducing mortality, liver transplants, and overall healthcare costs. The initiative ...

Sofosbuvir, velpatasvir; 150mg/37.5mg, 200mg/50mg; per packet. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a ...

Medically reviewed by Jay N. Yepuri, MD Liver inflammation describes a condition commonly known as hepatitis. While people often take hepatitis to mean viral hepatitis (such as hepatitis A, B, or C), ...